Supply of High-quality Apalutamide API and Intermediates
Shandong Haohong Biotechnology Co., Ltd is mainly focuses on the development of anti-cancer, anti-diabets series of API and its advanced intermediates. The main products include Bicalutamide, enzalutamide, apalutamide, macitentan, cabozantinib, ceritinib, empagliflozin, tofacitinib citrate, and alectinib,etc. In line with the concept of "truth-seeking, innovation and integrity", we had exported our products to the United States, European countries, Japan, India, Bangladesh and other overseas markets. At present, Our company has dozens of advanced intermediates, all of which are commercialized.
Apalutamide (INN) (developmental code name ARN-509, also JNJ-56021927) is a non-steroidal antiandrogen that is under development for the treatment of prostate cancer. It is similar to enzalutamide both structurally and pharmacologically, acting as a selective competitive antagonist of the androgen receptor (AR), but shows some advantages, including greater potency and reduced central nervous system permeation. Apalutamide binds weakly to the GABAA receptor similarly to enzalutamide, but due to its relatively lower central concentrations, may have a lower risk of seizures in comparison.
The drug has been found to be effective and well-tolerated in clinical trials thus far, with the most common side effects reported including fatigue, nausea, abdominal pain, and diarrhea.
Apalutamide is currently in phase III clinical trials for castration-resistant prostate cancer.
Recently, the acquired F876L mutation of the AR identified in adv